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Abstract
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1
(PD-L1) have improved the survival of patients with non-small cell lung cancer (NSCLC). Still, many patients do not
respond to these inhibitors. PD-L1 (CD274) expression, one of the factors that influences the efficacy of immune
checkpoint inhibitors, is dynamic. Here, we studied the regulation of PD-L1 expression in NSCLC without targetable
genetic alterations in EGFR, ALK, BRAF, ROS1, MET , ERBB2 and RET . Analysis of RNA sequencing data from these
NSCLCs revealed that inferred IFN, EGFR and MAPK signaling correlated with CD274 gene expression in lung
adenocarcinoma. In a representative lung adenocarcinoma cell line panel, stimulation with EGF or IFN increased
CD274 mRNA and PD-L1 protein and membrane levels, which were further enhanced by combining EGF and IFN.
Similarly, tumor cell PD-L1 membrane levels increased after coculture with activated peripheral blood mononuclear
cells. Inhibition of the MAPK pathway, using EGFR inhibitors cetuximab and erlotinib or the MEK 1 and 2 inhibitor
selumetinib, prevented EGF- and IFN-induced CD274 mRNA and PD-L1 protein and membrane upregulation, but
had no effect on IFN-induced MHC-I upregulation. Interestingly, although IFN increases transcriptional activity
of CD274, MAPK signaling also increased stabilization of CD274 mRNA. In conclusion, MAPK pathway activity
plays a key role in EGF- and IFN-induced PD-L1 expression in lung adenocarcinoma without targetable genetic
alterations and may present a target to improve the efficacy of immunotherapy.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
After years of limited progress in the treatment
of advanced non-small cell lung cancer (NSCLC), a
major leap forward has been made with the introduction
of programmed cell death protein 1 (PD-1)/programmed
death-ligand 1 (PD-L1) targeting immune checkpoint
inhibitors. These have greatly improved the overall
survival of patients with advanced NSCLC, espe-
cially patients without targetable genetic alterations,
accounting for almost 60% of NSCLC [1–3]. Patients
with PD-L1-positive tumors generally respond bet-
ter to PD-1-targeted immune checkpoint inhibition.
However, discrepancies between observed PD-L1
expression and the benefit from treatment often occur
[4]; even in a preselected patient population with >50%
PD-L1-positive tumor cells, only 45–55% of patients
respond to therapy [5]. The limited value of tumor
PD-L1 as a biomarker may be caused by the highly
dynamic expression of PD-L1 due to the influence of
multiple factors [6]. The best characterized inducer of
PD-L1 expression in NSCLC is the pro-inflammatory
cytokine IFNγ, which is secreted by T cells [7,8]. PD-L1
on tumor cells binds to PD-1 on T cells, disrupting T
cell function and thereby preventing an effective tumor
immune response [9]. Oncogenic driver mutations, such
as mutations in EGFR, ALK and BRAF, are known
inducers of PD-L1 expression in NSCLC cells. In these
oncogene-activated cells, the PI3K/mTOR, JAK/STAT
and MAPK pathways are the main drivers of PD-L1
expression [10–13].
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
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Interestingly, EGFR wild-type NSCLC tumors have
higher levels of PD-L1 and tumor infiltrating lym-
phocytes, and respond better to PD-1/PD-L1-targeted
therapy compared with EGFR mutant NSCLC [1,2].
However, there are only limited data about the reg-
ulation of PD-L1 expression in NSCLC without
targetable genetic alterations [14–16]. A better under-
standing of PD-L1 regulation may provide a rationale
to combine immune checkpoint inhibitors with other
targeted agents. In the present study, we aimed to iden-
tify pathways regulating CD274 (PD-L1) expression in
this NSCLC subtype by using RNA sequencing data
from The Cancer Genome Atlas (TCGA) lung adeno-
carcinoma and squamous cell lung carcinoma datasets.
We functionally validated our findings using adeno-
carcinoma cell lines and cocultures with peripheral
blood mononuclear cells (PBMCs). Our results indicate
that growth factor-dependent MAPK signaling plays
an important role in basal and IFNγ-induced PD-L1
expression of lung adenocarcinoma without targetable
genetic alterations.
Materials and methods
TCGA data retrieval and analysis
TCGA RNA sequencing V2 and mutation data for lung
adenocarcinoma and squamous cell carcinoma [17,18]
were obtained from the cBioportal for Cancer Genomics
[19] on 14 October 2018. We selected 230 adenocar-
cinoma and 178 squamous cell carcinoma samples
with complete RNA sequencing and whole exome
sequencing data. Data were analyzed and visualized
using R (available from https://www.r-project.org/)
and the R studio interface 1.1.453 (available from
https://www.rstudio.com/) and ggplot2 package for R
3.5.1 (available from http://ggplot2.tidyverse.org). Our
analysis was performed in 159 lung adenocarcinoma
and 166 squamous cell lung carcinoma samples without
targetable alterations in EGFR, ALK, ROS1, BRAF,
ERBB2, MET or RET [20]. TCGA RNA sequencing
data were normalized in two steps. Each expression
value was first log10-transformed and then Z-score
normalized by subtracting the mean expression of each
gene and dividing by the standard deviation. Next,
MAPK pathway activation was inferred according to
the methods of previously described gene signatures
for rat sarcoma (RAS) and MEK activation [21,22].
Inferred pathway activities were calculated as described
in the original articles. IFNγ signaling was inferred
using IRF1 and STAT1 mRNA levels; STAT3 signaling
by using STAT3 gene expression. The correlation of
CD274 (PD-L1) mRNA level with these signature
scores was calculated using Spearman correlation. To
complement this analysis, gene set enrichment analysis
(GSEA) was performed on the same samples, using the
hallmark PI3K and IFNG signatures in addition to the
previously mentioned signatures. Furthermore, we used
the C6 oncogenic signaling MEK and EGFR signatures
and an alternative PI3K signature. However, the authors
doubt whether their signatures, developed for estrogen
receptor-positive breast cancer, can be used for other
tumor types (http://software.broadinstitute.org/gsea/
index.jsp [23,24]). GSEA was performed with 1000
permutations with Z-score normalized CD274 gene
expression as a continuous phenotype label. Genes were
ranked based on the Pearson Metric.
Cell culture
The human NSCLC cell lines HCC827, H292, A549,
H358 and H460 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
H322 was obtained from Sigma-Aldrich (St Louis,
MO, USA). All cell lines are from the adenocarci-
noma histological subtype, except H292, which is an
adenocarcinoma-like mucoepidermoid carcinoma. Cells
were quarantined until screening for microbial contami-
nation and mycoplasma was performed and proven to be
negative. Cells were tested and authenticated using short
tandem repeat profiling. Cells were grown in RPMI
with 10% FCS, with 2 mM glutamine added for H322
cells. All cells were incubated in a humidified atmo-
sphere with 5% CO2 at 37
∘C.
Antibodies and treatments
The details of antibodies used for flow cytometry
and Western blotting are provided in Supplementary
material, Table S1. Western blotting detection was
performed using Lumi-Light Western blotting substrate
(Roche Diagnostics, Basel, Switzerland). Cells were
treated under normal culture conditions with EGF,
HGF, IFNγ (each from R&D Systems, Minneapolis,
MN, USA), erlotinib (LC Laboratories, Woburn, MA,
USA), cetuximab (Merck KGaA Darmstadt, Germany),
selumetinib (AZD6244, Axon Medchem, Reston,
VA, USA), XL147 (LC Laboratories), everolimus
(Selleckchem, Houston, TX, USA), BMS911543
(Selleckchem) and actinomycin D (Sigma-Aldrich).
siRNA transfection
Cells were transiently transfected with an siRNA tar-
geting STAT3 (Eurogentec, Liege, Belgium) or a neg-
ative control siRNA (12935300, Invitrogen, Carlsbad,
CA, USA) using oligofectamine (11252011, Invitrogen)
in Opti-MEM (51985, Invitrogen) according to the man-
ufacturer’s instructions. Twenty-four hours after trans-
fection, cells were treated with indicated ligands and
treatments. After a total of 48 h, STAT3 knockdown effi-
ciency and proteins of interest were analyzed byWestern
blotting or flow cytometry. All experiments were per-
formed in triplicate.
Flow cytometric analysis
Cells were harvested using trypsin and kept on ice
in PBS with 2% FCS during the entire protocol. After
staining, cells were kept in PBS with 2% FCS until
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 52–64
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analysis. Cells were incubated with anti-PD-L1 anti-
bodies at 10 μg/ml for 45min. Bound antibody was
detected by incubating cells with goat anti-mouse IgG
at a 1:50 dilution for 45min. Measurements were per-
formed on a BD Accuri C6 flow cytometer (BD Bio-
sciences, Franklin Lakes, NJ, USA). Data analysis was
performed with FlowJo v10 (Tree Star, Ashland, OR,
USA) and surface receptor expression was expressed
as mean fluorescence intensity (MFI). Measurements
were corrected for background fluorescence and unspe-
cific binding of the secondary antibody. Unless stated
otherwise, all experiments were performed in triplicate.
Western blot
Lysates from cells were made using mammalian pro-
tein extraction reagent with protease and phosphatase
inhibitors diluted 1:100 (Thermo Fisher Scientific,
Waltham, MA, USA). Proteins were separated using
SDS-PAGE. Target proteins were detected with the
appropriate antibodies and images were captured
using a digital imaging system (Bio-Rad, Hercules,
CA, USA). All bands were observed around the size
specified in supplementary material, Table S2A. Den-
sitometric quantitation of target proteins was calculated
using ImageJ relative to loading controls β-actin or
GAPDH depending on the target protein size (see
supplementary material, Table S2B for data).
Viability assays
H292 (8000 cells/well), H358 (20 000 cells/well), A549
(2000 cells/well), H322 (10 000 cells/well) and H460
(2000 cells/well) cells were plated in 96-well plates
in their respective media and after 6 h erlotinib or
selumetinib was added in concentrations ranging from
0.01 to 10 μM. After 96 h, cells were fixed in 3.7%
formaldehyde and stained using crystal violet. After
washing, bound crystal violet was dissolved using 10%
ethanoic acid and absorption measured at 590 nm. Cell
survival was calculated as a percentage of untreated con-
trol. All proliferation assays were performed three times
in triplicate.
RNA sample collection and qRT-PCR
Total RNA was extracted using Trizol reagent (Invit-
rogen) and possible DNA contamination was removed
using TURBO DNase ambion (Life Technologies,
AM2238). RNA was then reverse transcribed to cDNA
with M-MLV reverse transcriptase (Thermo Fisher
Scientific, 28025013). Real-time PCR was per-
formed using IQ SYBR Green Supermix (Bio-Rad,
1708886) according to the manufacturer’s instruc-





The relative gene expression was calculated using the
double delta CT method and GAPDH as a loading
control [25]. All qPCR experiments were performed
three times in duplicate.
Coculture experiments
Human PBMCs were isolated from whole blood
by Ficoll-Paque density centrifugation (Ficoll-Paque
PLUS, GE Healthcare Life Sciences, Marlborough,
MA, USA) from peripheral blood donated by healthy
volunteers. The acquired PBMCswere activated for 72 h
using human T-activator CD3/28 beads (Thermo Fisher
Scientific) and 100 IU/ml IL-2 (Proleukin, Novartis,
Basel, Switzerland) in the presence of tumor cells.
Separately, tumor cells were seeded into 96-well plates
at a density of 1× 104 cells/well for 48 h. Then, the
pre-activated PBMCs were added into the coculture
system at a 5:1 ratio of PBMCs to tumor cells. During
coculture, cells were treated with EGF (20 ng/ml),
erlotinib (10 μM) and selumetinib (10 μM). After 24 h
of coculture, cell-free supernatant was collected for
IFNγ analysis by ELISA (Sino Biological, Beijing,
PR China). Cells were harvested for flow cytometric
measurement of membrane PD-L1. In separate experi-
ments, tumor cells were cultured in cell-free supernatant
from activated PBMCs. Membrane PD-L1 levels were
determined after 24 h using flow cytometry.
Statistics
Cell line experiments were assessed for differences
with unpaired two-tailed Student’s t-test or two-way
ANOVA followed by Bonferroni post-hoc or Dunnett’s
test. Results are represented as means±SD. A P value<
0.05 was considered statistically significant. Statistical
analyses were performed using GraphPad Prism soft-
ware (version 6.0 GraphPad software).
Results
MAPK pathway activation correlates with CD274
gene expression in lung adenocarcinoma
To study which EGFR-related signaling pathways reg-
ulate CD274 expression in NSCLC without targetable
genetic alterations, we collected RNA sequencing data
of 159 lung adenocarcinoma and 166 squamous cell
lung carcinoma samples from TCGA, excluding sam-
ples with driver mutations in EGFR, ALK, BRAF, ROS1,
MET , ERBB2 and RET . Activating KRAS mutations
were present in 75 of the lung adenocarcinoma and in
one of the squamous cell carcinoma samples. Activation
of the MAPK pathway was determined using validated
signatures for RAS or MEK activation [21,22]. MAPK
pathway activation scores were significantly higher in
KRAS mutant samples (see supplementary material,
Figure S1A). In addition, there was a moderate corre-
lation between RAS and MEK activation scores (see
supplementary material, Figure S1B). Interestingly, in
adenocarcinomas, but not in squamous cell carcinomas,
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 52–64
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Figure 1. MAPK and IFNγ signaling correlate with CD274 expression in lung adenocarcinoma tumors without targetable genetic alterations.
RNA sequencing data from all TCGA lung adenocarcinoma and squamous cell lung carcinoma samples without targetable genetic alterations
were collected. RNA sequencing data were Z-score normalized after 10log transformation. (A) Spearman correlation between CD274 and
RAS activation score or MEK activation score in all samples. (B) Spearman correlation between CD274 expression and RAS activation score or
MEK activation score in KRAS wild-type lung adenocarcinoma samples. (C) Spearman correlation between STAT1 and CD274 in all samples.
LUSC, squamous cell lung carcinoma.
RAS and MEK activation scores correlated with CD274
gene expression (Figure 1A, Table 1). Subset analysis
showed that these correlations were strongest in KRAS
wild-type lung adenocarcinomas (Figure 1B and sup-
plementary material, Figure S1C). STAT3 mRNA levels
did not correlate with CD274 in any subset (Table 1).
In both histological subtypes, mRNA levels of STAT1
and IRF1, important mediators of IFNγ, correlated with
CD274 (Figure 1C and supplementary material, Figure
S1D), CD8A (rs = 0.73, rs = 0.72), and IFNG (rs = 0.71,
rs = 0.74), respectively. Inferred MEK and RAS activ-
ities were not significantly correlated with STAT1 (rs
= 0.12, p= 0.27; rs = 0.1, p= 0.36). Interestingly, a
combined score for MAPK and IFNγ signaling, created
by adding up 0 to 1 rescaled MEK activation scores
and STAT1 levels, correlated more strongly with CD274
mRNA levels (see supplementary material, Figure S1E).
GSEA using RAS, MEK and the hallmark IFNG sig-
natures largely confirmed these findings. In addition,
GSEA of the PI3K hallmark signature suggested a link
between PI3K/mTOR signaling andCD274 (see supple-
mentary material, Table S3). This suggests that activa-
tion of the MAPK, PI3K/mTOR and IFNγ pathways is
related to increased CD274mRNA levels in lung adeno-
carcinomas without targetable genetic alterations.
EGF increases IFNγ-induced PD-L1 expression in
NSCLC cells without targetable genetic alterations
A panel of lung adenocarcinoma cell lines without tar-
getable genetic alterations, including a KRAS wild-type
(H322), three KRAS mutant (A549, H358 and H460)
and a KRAS wild-type adenocarcinoma-like mucoepi-
dermoid carcinoma cell line (H292) [26], was selected
to further investigate the relationship between EGFR
and IFNγ pathway activation with PD-L1 expression.
Membrane PD-L1 was observed in all cell lines, irre-
spective of KRAS mutation status (see supplementary
material, Figure S2A). The highest levels were found in
H292, H358 and H460 cells. Levels were comparable
with PD-L1 membrane levels of HCC827 EGFRmutant
NSCLC cells (see supplementary material, Figure S2A).
We wondered whether IFNγ and EGF, known activators
of the EGFR, PI3K/mTOR andMAPK pathways, would
increase PD-L1 levels in our panel. Treatment with
EGF or IFNγ for 24 h using physiologically relevant
concentrations (20 ng/ml) [27,28] increased membrane
PD-L1 in both KRAS wild-type and KRAS mutant cells
(Figure 2A,B).Moreover, exposure of cells to EGF com-
bined with IFNγ resulted in a further increase in PD-L1
compared with IFNγ alone. Prolonged incubation up
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 52–64
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Table 1. Correlation between inferred MAPK, PI3K/mTOR and IFNγ pathway activity, and CD274 gene expression in NSCLC subtypes
Adenocarcinoma LUSC
Non-targetable





RAS score rs 0.42 0.32 0.47 0.52 −0.06
p 4.1× 10−8 0.006 7.6× 10−6 0.005 ns
MEK score rs 0.40 0.21 0.51 0.13 0.04
p 2.0× 10−7 ns 7.5× 10−7 ns ns
STAT3 rs −0.15 −0.20 −0.10 −0.08 0.11
p ns ns ns ns ns
STAT1 r 0.54 0.66 0.48 0.33 0.43
p < 2.2× 10−16 < 2.2× 10−16 4.9× 10−6 ns 1.6× 10−8
IRF1 r 0.49 0.43 0.53 0.47 0.33
p 8.8× 10−11 2.0× 10−4 2.0× 10−7 0.01 2.1× 10−5
mt, mutant; ns, not significant; rs, Spearman’s rho; wt, wild-type.
to 72 h further enhanced PD-L1 in H292 and H358
(Figure 2C).
To gain insight into the underlying mechanism of
the increase in surface PD-L1, we measured total
PD-L1 protein and CD274 mRNA levels. The EGF-
and IFNγ-induced increase in surface expression was
reflected in a strong induction of both mRNA and
total protein levels (Figure 2D,E). EGF stimulated
the MAPK and PI3K/mTOR pathways, as signified
by increased levels of phosphorylated ERK 1 and 2
(pERK1/2) and phosphorylated ribosomal S6 protein
(pS6), respectively (Figure 2E and supplementary mate-
rial, Figure S2B). IFNγ strongly increased STAT1 and
phosphorylated STAT1 (pSTAT1) levels for up to 72 h.
Taken together, these results indicate that EGF and IFNγ
activate the MAPK, PI3K/mTOR and STAT1 pathways,
and concurrently increase PD-L1 mRNA, protein and
membrane levels.
EGFR inhibition prevents EGF- and IFNγ-induced
PD-L1 upregulation
To analyze the regulation of membrane PD-L1 by EGFR
and STAT1 signaling, H292 and H358 cells were treated
with EGF and IFNγ in the presence of anti-EGFR mon-
oclonal antibody cetuximab or EGFR small molecule
inhibitor erlotinib. Interestingly, cetuximab and erlotinib
prevented not only EGF-induced but also IFNγ-induced
upregulation of CD274 mRNA levels, which was
reflected in reduced membrane and total PD-L1 protein
levels (Figure 3A,B and supplementary material, Figure
S3A). Data from multiple experiments showed that
erlotinib reduced basal PD-L1 membrane levels in
H358 but not H292 cells (see supplementary material,
Figure S3B). Erlotinib had a similar effect on EGF-
and IFNγ-induced PD-L1 membrane levels in two
other cell lines but not in the erlotinib-resistant H460
cell line, as expected (see supplementary material,
Figure S4A). EGFR inhibition effectively reduced
EGF-dependent MAPK and PI3K/mTOR signaling
and modestly decreased IFNγ-induced upregulation of
(p)STAT1 (Figure 3B). These results indicate that EGF-
and IFNγ-induced CD274 mRNA and PD-L1 protein
and membrane levels are dependent on EGFR-mediated
signaling.
MAPK pathway inhibition prevents PD-L1 induction
by EGF and IFNγ
Next, we assessed the involvement of MAPK
and PI3K/mTOR signaling in PD-L1 upregulation.
Selumetinib, an inhibitor of MEK1/2, almost com-
pletely suppressed induction of CD274 mRNA by
EGF and IFNγ in H292 and H358, and diminished the
induction of protein and membrane levels (Figure 4A,B
and supplementary material, Figure S3A). Moreover,
selumetinib decreased basal PD-L1 membrane levels
in H292 and H358 cells (see supplementary material,
Figure S3B). Selumetinib effectively inhibited MEK1/2
activity, as reflected in the reduction in pERK1/2
levels, and had a moderate effect on pSTAT1 levels.
The effect of selumetinib on membrane PD-L1 was
confirmed in additional cell lines (see supplementary
material, Figure S4A). PI3K inhibitor XL147 and
mTORC1 inhibitor everolimus partially suppressed
EGF- and IFNγ-induced PD-L1 in H292 cells, but they
had no effect on the induction of membrane PD-L1
(Figure 4A,B). At these concentrations, both drugs
effectively inhibited PI3K/mTOR pathway activity, as
indicated by reduced pAKT and pS6 levels (Figure 4B).
We pursued studying the MAPK pathway because of
its major influence on PD-L1 expression. A wide range
of selumetinib and erlotinib concentrations was used
to determine if lower drug concentrations also reduce
PD-L1 expression. After 24 h, even the lowest selume-
tinib concentration (0.1 μM) strongly reduced pERK lev-
els, as well as PD-L1 protein and membrane expression
levels of H292 and H358 cells in both control and EGF-
and IFNγ-stimulated cells (see supplementary material,
Figure S3C). Treatment with this selumetinib concentra-
tion for 96 h resulted in a growth reduction of 30–50%
(see supplementary material, Figure S3D), indicating
that PD-L1 expression can bemanipulatedwith aMAPK
activity inhibitor using concentrations that only partially
reduce cell growth. In line with these results, selume-
tinib had a similar moderate effect on growth in the
other three cell lines (see supplementarymaterial, Figure
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 52–64
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Figure 2. EGF and IFNγ induce PD-L1 in NSCLC cell lines. (A and B) NSCLC cell lines without targetable genetic alterations treated with
20 ng/ml EGF, 20 ng/ml IFNγ or both. After 24 h, PD-L1 membrane expression was measured using flow cytometry (Student’s t-test; ns= not
significant, *p< 0.05, **p< 0.01 compared with IFNγ, n= 3–11, combined data from all other figures). (C) Membrane PD-L1 levels measured
using flow cytometry in cells treated with EGF and IFNγ for 24 or 72 h. Data are represented as MFI/mean corresponding control MFI, n= 3.
(D) PD-L1 mRNA levels measured using RT-qPCR on H292 and H358 treated with 20 ng/ml EGF or IFNγ or both for 24 h. Data were analyzed
using the double delta CT method and GAPDH as a loading control. (E) Western blotting of protein extracts from H292 and H358 treated
with 20 ng/ml EGF, 20 ng/ml IFNγ or both for 1, 24, 48 and 72 h. Actin was used as a loading control. Con, untreated control.
S4B). Similar results were observed with erlotinib. In
conclusion, MAPK pathway inhibitors suppress EGF-
and IFNγ-induced CD274 mRNA and PD-L1 protein
and membrane expression at concentrations that have a
small effect on growth.
HGF induces surface PD-L1 via the MAPK pathway
We investigated whether activation of the MAPK
pathway via HGF receptor (cMET) has a similar
effect on PD-L1 as MAPK activation by EGFR.
Overexpression of cMET and its ligand HGF occur
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 52–64
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Figure 3. EGFR inhibition prevents EGF- and IFNγ-induced PD-L1 expression. H292 and H358 cells were treated with 20 μg/ml cetuximab
or 10 μM erlotinib with and without cotreatment with 20 ng/ml EGF, 20 ng/ml IFNγ or both for 24 h. (A) Membrane PD-L1 measured using
flow cytometry (two-way ANOVA with Dunnett’s multiple comparisons test; **p< 0.01, ***p< 0.001 compared with untreated control). (B)
Cellular protein levels measured using Western blotting. Actin was used as a loading control. Data from a representative experiment are
shown. C, untreated control; E+ I, EGF+ IFNγ.
frequently in lung adenocarcinoma tumors [29]. More-
over, upon binding of HGF, cMET is known to activate
PI3K/mTOR, MAPK and JAK/STAT pathways, similar
to EGFR [30]. HGF enhanced PD-L1 expression and
augmented IFNγ-induced PD-L1 expression in the
cMET-positive H292 and H358 cell lines (Figure 4C).
Combining HGF and EGF had no additional effect
on membrane PD-L1 levels compared with single
EGF or HGF treatment. Also, in this case, selumetinib
effectively prevented HGF-induced effects on PD-L1
levels in both cell lines, whereas erlotinib only showed
efficacy in H292 cells. Taken together, these results
demonstrate that, irrespective of the upstream growth
factor receptor, MAPK pathway activation is essential
for PD-L1 membrane expression.
MAPK pathway inhibition does not interfere
with IFNγ-induced MHC-I upregulation
Expression of MHC-I is critical for tumor cell antigen
presentation and the anti-tumoral immune response
[31]. Because both MAPK and IFNγ signaling can
influence MHC-I expression, we wondered whether
EGFR and MEK1/2 blockade could interfere with
its expression in our cell lines [32–34]. IFNγ, but
not EGF, increased MHC-I membrane expression in
four of five cell lines (Figure 4D and supplementary
material, Figure S4C). Moreover, MAPK pathway
inhibition using erlotinib and selumetinib did not influ-
ence IFNγ-induced upregulation of MHC-I expression,
suggesting that MHC-I-mediated tumor cell antigen
presentation will not be impaired by these drugs.
MAPK signaling increases stability of CD274 mRNA
To investigate the role of STAT signaling in MHC-I
and PD-L1 expression after IFNγ or EGF treatment, we
inhibited STAT1 and STAT3, major transcription fac-
tors downstream of IFNγ and EGFR signaling, respec-
tively [6,35]. Suppression of STAT1 signaling using
JAK2 inhibitor BMS911543 prevented IFNγ-induced
PD-L1 and MHC-I expression, but not EGF-induced
PD-L1 expression (Figure 5A and supplementary mate-
rial, Figure S5A). Also, inhibition of STAT3 using
an siRNA had no influence on PD-L1 regulation by
MAPK signaling (see supplementary material, Figure
S5B). Therefore, we hypothesized that the MAPK path-
way may regulate PD-L1 at a post-transcriptional level.
KRAS mutations were recently shown to be involved
in post-transcriptional regulation of basal PD-L1 lev-
els through modulation of CD274 mRNA stability [36].
To study whether MAPK signaling controls the stability
of IFNγ-induced CD274 mRNA, KRAS wild-type and
mutant cells were pretreated with IFNγ followed by the
addition of the transcriptional blocker actinomycin D
[37]. Blocking transcription for 90min halved CD274
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 52–64
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Figure 4. Selumetinib effectively decreases growth factor- and IFNγ-induced PD-L1 expression. H292 and H358 cells were treated with
10 μM XL147, 10 μM everolimus or 10 μM selumetinib, with and without cotreatment with 20 ng/ml EGF, 20 ng/ml IFNγ or both for 24 h.
(A) Flow cytometry of membrane PD-L1 (two-way ANOVA with Dunnett’s multiple comparisons test, *p< 0.05, ***p< 0.001 compared with
ligand-stimulated control). (B) Western blot of cellular protein levels. Actin was used as a loading control. Data are from a representative
experiment (n= 2). (C) Membrane PD-L1 and (D) MHC-1 levels measured by flow cytometry of H292 and H358 cells treated with 10 μM
erlotinib or 10 μM selumetinib, with and without cotreatment with 20 ng/ml EGF, 20 ng/ml HGF, 20 ng/ml IFNγ or a combination for 24 h.
In (C), two-way ANOVA with Dunnett’s multiple comparisons test, *p< 0.05, **p< 0.01, ***p< 0.001 compared with ligand-stimulated
control. (D) Student’s t-test, **p< 0.01. ns, not significant; C, untreated control; XL, XL147; Ev, everolimus; Selu, selumetinib. H+ E+ I,
HGF+ EGF+ IFNγ.
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Figure 5. MAPK signaling increases CD274 mRNA stability. (A) Membrane PD-L1 using flow cytometry and cellular protein levels by Western
blotting in cells treated with BMS911543 in the presence of 20 ng/ml EGF and IFNγ for 24 h. Blot from a representative experiment (n= 2).
(B) RT-qPCR of CD274 mRNA levels (PD-L1) in H292 and H358 cells initially treated with IFNγ for 24 h, then with 5 μg/ml actinomycin
D for 10 min, followed by 20 ng/ml IFNγ, 20 ng/ml EGF or 10 μM selumetinib for 80min. Data were analyzed using the double delta CT
method and GAPDH as a loading control (two-way ANOVA with Tukey’s test, *p< 0.05, **p< 0.01, ***p< 0.001). Con, untreated control;
E+ I, EGF+ IFNγ; ActD, actinomycin D.
levels (Figure 5B). Interestingly, degradation of CD274
was counteracted by EGF-induced activation of MAPK
signaling. Accordingly, inhibition of MAPK signaling
with selumetinib accelerated CD274 degradation and
decreased the stabilization by EGF. These results show
that MAPK signaling influences the stability of CD274
mRNA, contributing to regulation of PD-L1 protein and
membrane expression.
MAPK pathway inhibition decreases PBMC-induced
PD-L1 surface expression
To study the relationship between immune cell acti-
vation and PD-L1 expression of tumor cells, we per-
formed cocultures of PBMCs and NSCLC cells. After
24 h coculture, membrane PD-L1 and MHC-I were
strongly induced in tumor cells (Figure 6A,B). Condi-
tioned medium from activated PBMCs contained IFNγ
(30 ng/ml) in comparable levels to our other experiments
and also strongly induced membrane PD-L1, indicating
that IFNγ may be involved in PBMC-induced PD-L1
(see supplementary material, Figure S6A,B). Similar to
our previous experiments, EGF further enhanced tumor
cell MAPK pathway activity and PD-L1 expression,
which was counteracted by erlotinib and selumetinib,
without influencing MHC-I (Figure 6A,B and supple-
mentary material, Figure S6A). Our results indicate that
MAPK pathway inhibition can reduce tumor cell PD-L1
in a more complex coculture system, without interfer-
ing with MHC-I induction in tumor cells, potentially
improving the immunogenicity of these cells.
Discussion
In this study we revealed a correlation between MAPK
pathway activation and CD274 expression in lung
adenocarcinomas without targetable genetic alterations
using TCGA RNA sequencing data. Subsequently, we
demonstrated the importance of MAPK signaling in the
upregulation of PD-L1 by growth factors and IFNγ in
lung adenocarcinoma cell lines, which was mediated
through CD274 mRNA stability and STAT1 activation
(Figure 6C). Inhibition of the MAPK pathway pre-
vents growth factor-, IFNγ- and PBMC-induced PD-L1
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Figure 6. Erlotinib and selumetinib prevent PBMC-induced PD-L1, but not MHC-I expression, in NSCLC cells. (A) H292 and H358 cells
were cocultured with 72 h pre-activated PBMCs from healthy volunteers at a ratio of five PBMCs per tumor cell. During coculture, cells
were treated with 20 ng/ml EGF, and 10 μM erlotinib or 10 μM selumetinib. Membrane PD-L1 was measured by flow cytometry after 24 h
(two-way ANOVA with Bonferroni’s multiple comparisons method, **p< 0.01, ***p< 0.01 compared with control + pre-activated PBMCs).
(B) Membrane MHC-I measured using flow cytometry (two-way ANOVA, *p< 0.05, **p< 0.01 compared with control). R, resting PBMCs;
A, activated PBMCs. (C) Proposed model for the role of IFNγ and MAPK signaling in PD-L1 regulation in lung adenocarcinoma. IFNγ derived
from tumor infiltrating immune cells induces CD274 transcription in tumor cells through activation of JAK/STAT signaling. CD274 mRNA
is translated into PD-L1 protein, which is transported to the cell membrane. Growth receptor- and mutated KRAS-induced MAPK signaling
increases STAT signaling, potentially adding to transcriptional activity. Also, MAPK signaling increases the stability of CD274mRNA, resulting
in increased mRNA and protein levels, and subsequently increasing PD-L1 membrane expression.
upregulation, whereas it does not interfere with MHC-I
expression. Taken together, these results indicate that
MAPK pathway inhibition may improve tumor cell
immunogenicity of lung adenocarcinomas without
targetable genetic alterations, comprising almost 60%
of all lung adenocarcinoma tumors in the Western
world [3].
Our TCGA analysis suggests that MAPK pathway
activity and CD274 gene expression are primarily con-
nected in lung adenocarcinoma, but not in squamous
cell carcinoma of the lung. Targeting the MAPK path-
way is especially interesting in lung adenocarcinoma,
because these tumors have a more active MAPK path-
way and more frequently harbor KRAS mutations com-
pared with squamous cell carcinoma tumors [38,39].
Intriguingly, this is also the subtype where tumor cell
PD-L1 has predictive and prognostic value [40,41]. Our
study shows that MAPK pathway inhibition prevents the
induction of CD274 mRNA by EGF and IFNγ through
two separate mechanisms (Figure 6C). First, a moderate
dose-dependent reduction of STAT1 and pSTAT1 levels
upon inhibition of EGFR or MEK1/2 may lower CD274
transcription (see supplementary material, Figure S3C).
This might be due to inhibition of the eukaryotic ini-
tiation factor 4F (eIF4F) translation initiation com-
plex, which is a downstream effector of the MAPK
pathway and essential for cap-dependent translation of
STAT1 mRNA [39,42]. Second, we observed reduced
CD274 mRNA stability upon inhibition of MEK1/2
or EGFR. This expands earlier data on basal PD-L1
expression in KRAS mutant cell lines, where MEK1/2
inhibition activates tristetraprolin, resulting in CD274
mRNA degradation [36]. Although CD274 transcrip-
tion and MHC-I-related transcription are both regu-
lated by STAT1 [6,35], MAPK inhibition, in contrast
to JAK2 inhibition, does not affect MHC-I expres-
sion, suggesting that MAPK activity primarily regulates
CD274 mRNA stability in lung adenocarcinoma cells.
At the protein level, PD-L1 can be affected by several
mechanisms, such as glycosylation, ubiquitination and
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stabilization at the cell membrane [15,43–45]. However,
we found no direct effect of EGF or IFNγ on CKLF-like
MARVEL transmembrane domain containing protein 6
(CMTM6) protein levels in H292 or H358 cells (data not
shown).
Our experiments demonstrated that both EGFR and
MEK1/2 inhibitors decrease EGF- and IFNγ-induced
PD-L1 expression, potentially increasing immunogenic-
ity of lung adenocarcinoma cells. Nevertheless, because
the MAPK pathway is downstream of a plethora of
growth factor receptors, downstream inhibition with
MEK1/2 inhibitors may be more effective to mod-
ulate PD-L1 than inhibition of specific growth fac-
tor receptors. This is supported by our finding that
MEK1/2 inhibition, but not EGFR inhibition, prevented
HGF-induced PD-L1 expression and by earlier findings
in renal cell carcinoma [46]. In vitro, we observed PD-L1
downregulation at selumetinib concentrations that had
a small effect on cell growth. Although in vitro exper-
iments do not perfectly model the tumor microenvi-
ronment, our results suggest that an immunomodula-
tory effect may already be present at lower selume-
tinib doses than previously utilized in NSCLC patients
[47,48]. The immunomodulatory role of MAPK sig-
naling is increasingly being recognized [49]. Multi-
ple studies using in vivo colon cancer models showed
that MEK inhibition potentiates the anti-tumor immune
response by preventing T cell apoptosis and decreas-
ing levels of myeloid suppressor cells and regulatory T
cells. This resulted in sustained tumor regression when
combined with PD-L1, PD-1 or CTLA-4 blocking treat-
ment [50–52]. In phase II and III studies of selume-
tinib in NSCLC patients, disappointing efficacy was
observed [47,48]. However, clear immune modulating
effects were observed, indicating that MAPK pathway
inhibition may increase the efficacy of immunotherapy.
Modulating PD-L1 expression is especially interesting
in NSCLC tumors without targetable genetic alterations,
because these have a more inflamed tumor microen-
vironment and respond better to immune checkpoint
inhibitors than tumors with targetable genetic alter-
ations, such as EGFR mutations [1,2]. These combi-
nation strategies are currently being tested in NSCLC
patients (NCT03600701, NCT03299088).
In conclusion, our results show the importance of
growth factor-induced MAPK pathway signaling in
PD-L1 expression in lung adenocarcinoma without
targetable genetic alterations. This provides a ratio-
nale to explore the combination of MAPK pathway
inhibitors with immunotherapy in this lung cancer
subtype.
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